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Background. Mutations and epigenetic aberrant signaling of growth factors pathways contribute to carcinogenesis. Recent
studies reveal that non-coding RNAs are controllers of gene expression. H19 is an imprinted gene that demonstrates maternal
monoallelic expression without a protein product; although its expression is shut off in most tissues postnatally, it is re-
activated during adult tissue regeneration and tumorigenesis. Moreover, H19 is highly expressed in liver metastasis derived
from a range of carcinomas. The objective of this study is to explore the role of H19 in carcinogenesis, and to determine its
identification as an anti-tumor target. Methodology/ Principle Findings. By controlling oxygen pressure during tumor cell
growth and H19 expression levels, we investigated the role of H19 expression in vitro and in vivo in hepatocellular (HCC) and
bladder carcinoma. Hypoxia upregulates the level of H19 RNA. Ablations of tumorigenicity of HCC and bladder carcinomas in
vivo are seen by H19 knockdown which also significantly abrogates anchorage-independent growth after hypoxia recovery,
while ectopic H19 expression enhances tumorigenic potential of carcinoma cells in vivo. Knocking-down H19 message in
hypoxic stress severely diminishes p57
kip2 induction. We identified a number of potential downstream targets of H19 RNA,
including angiogenin and FGF18. Conclusions. H19 RNA harbors pro-tumorigenic properties, thus the H19 gene behaves as
an oncogene and may serve as a potential new target for anti-tumor therapy.
Citation: Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, et al (2007) The H19 Non-Coding RNA Is Essential for Human Tumor Growth. PLoS
ONE 2(9): e845. doi:10.1371/journal.pone.0000845
INTRODUCTION
The phenotypic and gene expression similarities of tumor cells to
cells at different developmental stages are becoming apparent.
One specific example is the liver, in which hepatocytes, upon
malignant transformation, express developmentally regulated
genes such as a-fetoprotein. Hepatocellular carcinoma (HCC) is
the third leading cause of worldwide cancer deaths, most of those
(.79%) occurring in Asia. The etiology of the overwhelming
majority of HCC cases is associated with a chronic inflammatory
process, suppression of apoptosis with an enhanced ongoing cell
cycle activity. Although considerable effort has focused on
unraveling the molecular pathogenesis of HCC during the last
few years, constructive knowledge remains mostly unknown [1].
The application of array-based, high-throughput genomic tech-
nologies to measure global gene expression, chromosomal
alterations, and mutations have started to provide comprehensive
information on the molecular pathogenesis of human HCC [2]. A
tumor progression model for human HCC based on bioinformatic
analysis of genomic data was able to identify three subgroups of
patients with different degrees of tumor progression [3]. It is
apparent that hepatocarcinogenesis is dependent on numerous
genetic alterations [4]. Some of these changes could be linked to
specific etiological factors, including integration of the hepatitis B
virus (HBV) DNA, leading to chromosomal instability, insertional
instability or alteration of cellular gene expression, in particular
the HBV X transactivating gene. Aflatoxin B1-exposed patients
induces R249S mutation by an adduction mechanism in the tumor
suppressor protein p53 [5]. Vinyl chloride exposure induces
mutations in K-Ras, hepatocyte nuclear factor 1a (HNF1 a)
mutations associated with hepatocellular adenomas and adeno-
matosis polyposis coli (APC) germline mutations predisposing to
hepatoblastomas. In addition, there are numerous genetic
alterations which are etiologically nonspecific, including recurrent
gains and losses of chromosomes, alteration of TP53 gene,
activation of WNT/b-catenin pathway through CTNNB1/ b-
catenin and AXIN (axis inhibition protein) mutations, inactivation
of retinoblastoma and IGF2R (insulin-like growth factor 2
receptor) pathways through inactivation of RB1 (retinoblastoma
1), P16 and IGF2R. Furthermore, specific signaling pathways are
also tightly associated with subsets of HCC natural history. The
MET tyrosine-kinase receptor is a sensor of adverse microenvi-
ronmental conditions (such as hypoxia) that drives cell invasion
and metastasis through the transcriptional activation of a set of
genes [6]. Applying global gene expression profiling of wild type
and Met-deficient primary mouse hepatocytes facilitated the
identification of the Met-dependent gene expression signature
within a subset of HCC with poor prognosis and aggressive
phenotype [7]. We, as others, have also applied the global gene
expression profiling to unfold the specific signaling associated with
inflammation-induced HCC in the MDR2 knockout mice [8]. In
this specific model of inflammation-induced tumors, we provided
evidence that NFkB has a role in HCC progression [9]. Moreover,
we have previously reported on the role of additional inflamma-
tory signaling and microenvironment in tumor progression [10].
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suggesting alternative mechanisms for HCC development de-
pendent on liver residing inflammatory cells and innate immune
signaling [11]. In one specific case of inflammation-associated
tumors, our group reported that in HBV infection-associated
HCC, there was an increased level of the imprinted , non-coding
H19 RNA , suggesting its use as a tumor marker [12].
During the past few years, a wealth of information revealed the
importance of different types of non-coding RNAs in controlling
gene expression. X–inactivation is controlled by the non–coding
RNA transcript Xist through an epigenetic mechanism [13]. The
small non–coding microRNAs can be perceived as tightly linked to
carcinogenesis [14]. The H19 gene transcribes also to a non–
coding RNA [15]. H19 is an imprinted oncofetal gene that
demonstrates maternal monoallelic expression in fetal tissues, and
does not code for a protein. It is abundantly expressed in
embryogenesis, but shut off in most tissues after birth. The
imprinted cluster on the human chromosome 11p15.5 has been
implicated in a variety of disorders and cancer predisposition for
both pediatric and adult tumors. This observation initially places
the H19 gene as a candidate gene that fulfills a role in
tumorigenesis. H19 overexpression promotes tumorigenic proper-
ties of breast cancer cells in vivo [16]; its expression is necessary for
cell entry into S-phase after serum deprivation by E2F1 binding to
its promoter [17], and is negatively regulated by p53 [18].
Recently, it was shown that H19 repression was tightly associated
with de-differentiation of cells compared to undifferentiated
parental cells [19]. Furthermore, in the first report on the
importance of the Twist gene product in tumor metastasis, the
investigators showed that H19 is the highest differentially
expressed gene in metastatic tumor cell lines investigated [20].
Certain known carcinogens upregulate the level of the H19 RNA.
In a study aimed to identify changes in gene expression patterns in
the airway epithelium of disease-free smokers compared with
a matched group of nonsmokers, a dramatic elevation of H19
RNA levels was detected in the airway epithelium of smokers
without affecting loss of imprinting [21]. We have shown that N-
Butyl-N-(4-hydroxybutyl) nitrosamine (BBN) (a known carcinogen
of the bladder) added to the drinking water also induces the
expression of H19 gene in a rat model of bladder cancer in early
stages [22,23]. Moreover, diethylnitrosamine (a known carcinogen
of the liver) induces the expression of H19 RNA in a mouse model
of HCC [24]. More striking is the predictive value of H19 RNA
for tumor recurrence, and its prognostic significance [25]. H19 is
expressed in both epithelial and stromal components of human
invasive breast adenocarcinoma; in contrast , it was reported that
of all tumors of breast adenocarcinoma displaying a good prognosis
(grade I), only the stromal component expresses H19 [26].
Two recent reports have linked indirectly H19 to HCC
development: 1. c-Myc induced the expression of the H19
RNA. c-Myc binds to the E-boxes near the imprinting control
region to facilitate histone acetylation and transcriptional initiation
of the H19 gene . c-Myc also down-regulates the expression of
IGF2, the reciprocally imprinted gene at the H19/IGF2 locus
[27]. c-Myc upregulation is an important factor in HCC
development [28] as well as in many other tumors. 2. The H19
is reported to be a target gene for the hepatocyte growth factor
(HGF), further signifying the potential role of H19 RNA in HCC
development [29]. Interestingly, H19 RNA is upregulated in
HBV-associated HCC [30]. Furthermore, a biallelic expression of
H19 gene was found in human HCC patients [31] and in liver
neoplasms of albumin SV40 T-antigen-transgenic rats [32].
In the current study, we highlight a critical role of H19 RNA in
tumor development. Cognizant of the role of hypoxia in
enhancing the signaling through the HGF/c-Met pathway, we
investigated as an initial step the effect of hypoxia on H19
expression in HCC. Moreover, our previous results point to
a growth advantage role of H19 RNA in serum stress, and
modulation of the expression of genes that are linked to angiogenesis
[33]. In this study, we show that hypoxia strongly upregulates H19
RNA level. We have also investigated the expression of additional
imprinted genes from the H19 gene cluster and showed that
knocking down H19 RNA suppresses p57
kip2 expression. By
applying whole genome expression profiling, we showed that H19
knockdown modulates the expression of genes involved in
angiogenesis, survival and tumorigenesis in hypoxic stress. We
further analyzed the functional consequences of these data and
showed that cells that are devoidof H19 expression inhypoxic stress,
fail to form colonies in soft agar after hypoxia recovery as opposed to
cells that possess H19. Furthermore, silencing H19 expression
attenuates tumor growth in vivo. Altogether, these results reveal that
H19 harbors an oncogenic activity in the liver through a mechanism
that needs further investigations.
MATERIALS AND METHODS
Cell culture
The human carcinoma cell lines (T24P, HepG2, Hep3B, HuH7
and UMUC3 used in this study were obtained from the American
Type Culture Collection (Manassas, VA, U.S.A.). The SNU group
of HCC cells was provided by M. Ozturk (Bilkent Univer.,
Ankara, Turkey). HepG2215 (HepG2-HBV producing cell line)
was provided by the group of Acs [34] and the FLC4 cells were
provided by the Miyamura [35] group; we have generated the
FLC4A10 (FLC4-HBV producing cell line) [36] . The cells were
maintained in DMEM-F12 (1:1) medium supplemented with 10%
fetal calf serum (inactivated at 55uC for 30 min), 25 mM HEPES
(pH 7.4), penicillin (180 units/ml), streptomycin (100 mg/ml) and
amphotericin B (0.2 mg/ml). Every 4 days, the cells were trypsinized
with 0.05% trypsin-EDTA solution (Beit Haemek, Israel) for 10 min
and re-plated again using the same initial densities.
In situ hybridization and immunohistochemistry
staining
H19 and a-fetoprotein expression were assessed by using both
radioactive and non-radioactive probes for the expression of the
H19 gene and immunohistochemistry, for the a-fetoprotein
expression according to Ariel et al. [12].
siRNAs selection and preparation
Four siRNAs targeting human H19 RNA and two negative
control siRNAs (targeting luciferase pGL3, or GFP) (Table S1)
were synthesized as ready-to-use duplexes by (Invitrogen U.S.A)
and designed with dTdT 39 overhangs on each strand. We selected
most H19 siRNA sequences as reported [37]. All sequences were
evaluated for gene specificity using the National Institutes of
Health Blast program. The freeze-dried siRNAs were dissolved in
RNase free- water and stored as aliquots at 280uC.
Cell culture conditions and transfection of siRNAs
Transfection of siRNAs was conducted with lipofectamine 2000
(Invitrogen, U.S.A.) in 12 well plates. The day prior to
transfection, the cells were trypsinized, counted, and seeded at
60,000 cells/well containing 1 ml DMEM medium without
antibiotics so that they were nearly at 50% confluence on the
day of transfection. Lipofectamine 2000 (3 ml) was incubated for
15 minutes with 100 ml serum-free OPTI-MEM medium (Invitro-
H19 Behaves as an Oncogene
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100 ml serum-free OPTI-MEM media; the formulation lasted
20 minutes. 195 ml of the mixture was applied to the cells and
incubated for another 48 hours without replacement of the
medium. For hypoxia- mimicking conditions, freshly prepared
CoCl2 was added at a final concentration of 100 mM, 24 hours
post transfection, and the cells were incubated for an additional
22 hours prior to RNA extraction. For hypoxic conditions, Hep3B
and UMUC3 cells were seeded and transfected as described
above. Twenty four hours post transfection, cells were either
placed into an Aneoropack rectangular jar (Mitsubishi Chemical
Company, Japan) and supplemented with BBL GasPak Plus
(Becton Dickson, Cock-eysville, MD, U.S.A.) to create hypoxic
conditions within an hour, or left under normal oxygen
concentration. The progression of the hypoxic environment was
monitored by a hypoxic indicator. Incubation lasted for an
additional 24 hours before RNA extraction.
RNA extraction and RT-PCR conditions
Reverse transcription of total RNA was performed as described,
except that 1 mg total RNA was used [33]. The PCR reaction for
H19 was carried out using Taq polymerase (Takara, Otsu, Japan)
for indicated cycles (in the legend of each figure) (94uC for 30 s,
58uC for 30 s, and 72uC for 30 s) preceded by 94uC for 5 min,
and a final extension of 5 min at 72uC for Hep3B cells and 29
cycles for UMUC3. PCR for Histone, GAPDH, b-actin and for
p57
Kip2 mRNAs was conducted as described [33].
Ex-vivo tumorigenic assay
For in vivo tumorigenicity, Hep3B and UMUC3 cells were
transfected in vitro by two different siRNA duplexes directed
against H19 RNA and an unrelated control siRNA (targeting Luc
or GFP), respectively as described above. Forty eight hours post
transfection, cells were injected subcutaneously into the dorsal
flank region of athymic female nude mice (6–8 weeks of age). An
additional control group received equal number of untreated
Hep3B cells. Cells were trypsinized, counted, and centrifuged and
re-suspended into sterile PBS (1X), so that there were about 5610
6
cells/ml. 250 ml of the suspension was injected into the dorsal flank
region of athymic nude mice. Fifteen and 30 days post injection,
tumors began to develop and their volumes were measured using
a caliper.
Anchorage-independent growth
Hep3B cells were seeded and transfected with GFP siRNA and
H19 siRNA as indicated above. Four hours post transfection, the
cells were placed under hypoxic condition for 24 hours. Cells were
washed by PBS, trypsinized, and counted. 2.5610
3 cells were
seeded in 6-well plates containing 0.3% top low-melt agarose-
0.8% bottom low-melt agarose. Cells were fed every 4 days and
colonies were counted microscopically after 4 weeks.
Cell proliferation analysis
Hep3B cells were seeded and transfected in 12 well plates as
described above with GFP siRNA and H19 siRNA. Twenty four
hours later, cells were washed twice with PBS, trypsinized and
counted. 5610
3 Hep3B cells transfected with GFP or H19 siRNAs
were seeded in quadruples in 96 well plates in DMEM media
containing 10% FCS, and further incubated for 24 hours before
MTS assay was performed. MTS assay was performed according
to the procedure provided by the supplier (Promega, USA). The
absorbance at 490 nm was recorded using ELISA plate reader.
Microarray analysis
Hep3B cells were seeded and transfected as described above with
H19 and GFP siRNAs. 24 hours later, cells were either exposed to
hypoxic stress or continued to grow under normal oxygen cell
culture conditions for an additional 24 hours. Total RNAs were
isolated 48 hours following siRNAs transfection, and were
subjected to reverse transcription, labeling and hybridization to
U133A2.0 gene chip arrays (Affymetrix, Santa Clara, CA)
containing about 18,400 transcript and variants, including
14,500 well characterized human genes. The siRNAs knockdown
experiments were performed non-simultaneously in duplicates.
PCR analysis confirmed the upregulation of H19 RNA in hypoxic
stress, and H19 knockdown by siRNA (data not shown). Although
genes affected could be categorized under different subheadings,
two categories will be dealt with here: (1) Genes that fall into the
category of hypoxia responsive genes, and are affected by H19
knockdown. (2) Genes that, although not responsive to hypoxia,
show modulation of expression by H19 knockdown in hypoxic
stress. The significance level was set at a false discovery rate with
an ANOVA P-value ,0.05. Genes modulated by at least two folds
(H19 siRNA versus GFP siRNA in hypoxic stress) are selected.
ANOVA analysis identified (87) genes which were significantly
differentially expressed falling into these two categories (p,0.05)
((60) up and (27) down).
Verification of selected genes by semi-quantitative
RT-PCR
To verify the different expression levels of mRNA measured by
microarray technology, we selected different up- and down-
regulated genes from the list of differentially expressed genes that
are modulated by H19 knockdown. The genes encoding for
angiogenin (ANG), insulin-like growth factor binding protein 4
(IGFBP4), v-akt murine thymoma viral oncogene homolog 1 (Akt-
1),, fibroblast growth factor 18 (FGF18) and Laminin beta receptor
(LBR) were analyzed. Three of them (ANG, FGF18 and Akt-1)
falls into the categories described above. The PCR primers
sequences are as follows: FGF18 (CCTGCACTTGCCTGT-
GTTTA For; CAGGGCCGTGTAGTTGTTCT Rev); ANG (
GTGCTGGGTCTGGGTCTGAC For; GGCCTTGATGCTG-
CGCTTG REV); v-AKT (GTTCTCCGGGTGTGGCCTCA-
GC For; CCATAGTGAGGTTGCATCTGG TGCC Rev); LBR
(GAATTTCCCTCCTCCTTTGC For, CGCGGTCCTGTAT-
TTTCATT Rev ); IGFBP4 (ACCCACGAGGACCTCTACAT-
CATCC For; CAGGCAGAGACAGGACTCAGACTC Rev). All
are written from 59 to 39 direction. Reverse transcription was
performed as indicated above using 1 mg total RNA.
Reverse-transcription and real time PCR reactions
cDNA was synthesized using 1 mg RNA in a total volume of 20 ml
reaction mix using the QuantiTect Reverse Transcription kit
(Qiagen), according to the manufacturer’s instructions. Relative
quantitation of cDNA samples were analyzed using an ABI Prism
7900HT sequence detection system, and the appropriate software
(SDS2.2) according to the manufacturer’s instructions (Applied
Biosystems, 850 Lincoln centre drive, Foster City, CA) and b-actin
was used as an internal standard. Two ml of the prepared cDNA
was amplified in a mixture of 20 ml containing 0.5 mM primers for
the H19 (59-TGCTGCACTTTACAACCACTG-39) upstream,
(59ATGGTGTCTTTGATGTTGGGC-39) downstream, and
0.9 mM of the b-actin primers (59-CCTGGGACCTGCCTG-
AACT-39) forward, (59-AATGCAGAGCGTCTTCCCTTT-39)
reverse. Whereas 0.1 mM fluorescent probe 6-FAM-TCGGCT-
CTGGAAGGTTGAAGCTAGAGGA-TAMRA) was used for
H19 Behaves as an Oncogene
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TGGTCAGAGAGAGACAC) was used. The PCR conditions
consisted of 1 cycle of 2 min at 50uC and 1 cycle of 10 min at
95uC followed by 40 cycles of 95uC for 15 sec, and 60uC for
60 sec. Sensitivity of the QPCR assays: To estimate the sensitivity
of the QPCR procedure, a plasmid DNA control which contains
part of the H19 cDNA region was used with 10-fold serial dilutions
of known quantities from 0.2ng (9610
7 copies) to 0.2610
27 ng
(#9 copies of plasmid DNA) for H19 analysis. For b-actin a DNA
control was used starting from 0.14ng (7610
8 copies) to
0.14610
28ng (#7 copies). Simultaneous amplifications of stan-
dard dilution series were then performed. The number of target
copies was determined using the standard curve created in the
same run. The QPCR assays were accepted when a positive signal
was detected in all positive control dilutions and no signal was
detected in the negative sample controls. These experiments were
performed in duplicate, at the very least.
Statistical analyses
Results are presented as mean +/2 standard error of the mean.
Differences between means were analyzed using the unpaired
Student’s t-test (two-tailed). None of the animals was excluded
from analysis. The probability value p,0.05 was considered
statistically significant.
RESULTS
H19 expression in HCC
From reports of others and those from our group, it appears that
H19 has a role in carcinogenesis. Increased expression of H19
RNA is shown in a large group of tumors (Table S2). HCC is also
associated with high H19 expression. In some cases, the high
expression is associated with the loss of imprinting (LOI) of the
H19 gene. LOI is a term that is conventionally used to describe the
change from imprinted monoallelic expression to biallelic
expression, and in most cases with an increase of expression.
Previous reports have shown the LOI of H19 in many tumor types
(Table S3). In specific cases of high H19 expression, we performed
an H19 RNA in situ hybridization analysis to depict the level of
expression. As could be seen in (Fig. S1), in some cases with H19
increased expression, the H19 message is abundantly expressed in
a human HCC tumor, at a much higher level than the traditional
HCC marker a-fetoprotein (AFP). As can be seen, AFP is also
expressed in the intravascular invasion of HCC, possibly teaching
that H19 could serve as a tumor marker. To further assess the
expression of H19 in HCC, we determined the level of H19 RNA
in a panel of HCC human tumor cell lines. As shown in (Fig. S2A,
S2C), H19 RNA is present in most HCC cell lines analyzed, but at
different levels. The human HCC cell line, Hep3B, was selected
for further analysis based on the observation that H19 is weakly to
modestly expressed in this cell line enabling to search for induction
conditions as described later. Moreover, H19 RNA is highly
increased in Hep3B formed tumors when the cells are sub-
cutaneously injected in the dorsa of nude mice in comparison to its
expression in vitro. This also holds true for other panels of cell
lines [38], and data not shown.
H19 RNA is induced in response to hypoxic stress
In the HCC cell line, Hep3B, there was an upregulation of H19
RNA in response to hypoxic stress (Fig. 1A). Similar data were
obtained in two cell lines of human bladder carcinoma, T24P
(data not shown) and UMUC3 (Fig. S5A).
To explore the involvement of the HIFa pathway in the
upregulation of H19 RNA during hypoxic stress, we tested
whether CoCl2, a reagent used to mimic the hypoxic condition,
could induce the expression of H19 RNA. Figure 1C shows that
H19 gene expression is mildly upregulated in response to the
addition of increasing concentrations of CoCl2 (50–400 mM). This
was also verified using quantitative PCR analyses (Fig. 1E). This
moderate upregulation of the H19 RNA by CoCl2 relative to its
strong upregulation in response to a real hypoxic condition could
indicate that the HIF1a pathway might only be partly responsible
for this upregulation.
Knocking down H19 RNA by siRNA in normoxic,
hypoxic and hypoxia-like culture conditions
To determine the most potent siRNA to be used for knocking
down H19, different H19 siRNAs were transfected into Hep3B
cells (Table S1). We examined the ability of these siRNAs to
knock-down the endogenous level of H19 RNA under both
normal–(normoxic) (Fig. 2A), or hypoxic-like conditions (Fig. 2B).
We used four different siRNAs targeting H19 RNA or an
equimolar pool of the four siRNAs. Significant decrease to
a varying extent of H19 RNA levels was detected by RT-PCR
analysis 48 hours post transfection, as compared with non-related
PGL3 siRNA duplex targeting luciferase or mock transfected
(without siRNA), respectively. The ability of three different H19
siRNAs to suppress the expression of the H19 gene was also tested
in hypoxic-like CoCl2 simulation (Fig. 2B). While H19 RNA is
moderately induced by CoCl2 simulation, a very significant
reduction is detected using three different siRNA targeting the
H19 transcript. Interestingly, the selected H19 siRNA imposed
a prolonged silencing effect on the level of H19 message in Hep3B
cells (Fig. S3). The silencing effect lasted up to 9 days following
transfection with nearly complete suppression shown at least six
days after transfection.
For real hypoxic conditions, only the most effective siRNA was
used. Hep3B cells were transfected with H19 siRNA or luc siRNA.
Twenty four hours post transfection, cells were either placed into
an Aneoropack rectangular jar under hypoxic conditions or
continued to grow under normal culture conditions for an
additional 24 hours before RNA extraction. Results show a very
significant upregulation of H19 RNA in response to hypoxic stress
in the cells which were transfected with luc siRNA which served as
a control. On the other hand, H19 siRNA nearly completely
knocked-down H19 RNA level under normal culture conditions,
and totally impeded the upregulation of H19 under hypoxic stress
(Fig. 3A). The expression level of two other genes, histone variant
H3.3 (Fig. 3B) and urokinase plasminogen activator receptor
(uPAR) (Fig. 3C), were not affected by H19 siRNA. These findings
suggest that H19 siRNA specifically and effectively knocks-down
the level of H19 RNA under both normoxic and hypoxic culture
conditions. These effects were also verified through a quantitative
RT-PCR on the H19 message levels under normoxic and hypoxic
conditions (Fig. 3D).
Ablation of tumorigenicity by H19 RNA knockdown
Next, we questioned whether H19 RNA is a tumor-associated
gene product or whether it is potentially harboring an oncogenic
potential by itself. Hep3B cells were transfected in vitro with H19
siRNA3 (Table S1) which proved to be the most potent siRNA in
this cell line, or with Luc-siRNA as a control. Forty eight hours
post transfection; cells were left to grow in vitro or used for
implantation for an ex- vivo study in CD-1 nude mice. For the in
vitro assessment, we used the MTS assay, which measures cell
proliferation. As shown in (Fig. S4), H19 knock-down did not
induce a statistically significant attenuation of cell proliferation of
H19 Behaves as an Oncogene
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in mice, we verify the knocking-down of H19 RNA determined by
RT-PCR analysis (data not shown). At this same time point, equal
numbers of the ex vivo/in vitro Hep3B transfected and non-
transfected cells (1.5610
6) were subcutaneously implanted into the
dorsa of CD-1 nude mice (groups of 7 mice for each transfected
group, and 4 mice for the non-transfected one – similar
experiments were repeated two additional times). Results showed
that HCC tumors, formed from Hep3B in vitro, transfected with
H19 siRNA, encountered a very significant retardation of tumor
growth, and in some cases, tumors did not form at all. About
a 82% reduction of both mean tumor volumes (Fig. 4B) and mean
tumor weights (Fig. 4A) was observed between the two transfected
cell lines; however, no significant differences were observed in both
mean tumor volumes and weights between tumors formed from
untreated Hep3B cells and those that were transfected with Luc
siRNA (data not shown). Measurements of two additional
experiments showed similar results, when collected two weeks
and one month after initial cell innoculation. Furthermore, in one
of the experiments, in the four mice receiving Hep3B transfected
with the siRNA-3 targeting the H19 message, we did not detect
even a trace of tumor as opposed to the five receiving Hep3B
transfected with luc siRNA.
Ectopic H19 expression enhances the tumorigenic
potential of bladder carcinoma cells in vivo
Next, we questioned whether the H19 message affects tumor
growth of other cell lineages. Two human bladder carcinoma cells
lines, TA11 and TA31, originating from the same parental cell
line, T24P, were either negative, (TA11
H19-ve) or high expressers
(TA31
H19high) of H19, respectively [33]. The T24P cell line was
stably transfected with an episomal vector that has an H19 full-
length cDNA placed in either the sense direction (the 6-kb H19
fragment spans the complete transcribed region of the human H19
gene and begins 48 nucleotides upstream of the transcriptional
start site), creating TA31, or the anti-sense direction (800 bp from
39 end), creating TA11. These cells were implanted subcutane-
ously into CD-1 mice. Tumor volumes were measured 15 days
post-implantation. As shown in (Fig. 5-top), tumors derived from
the TA11
H19-ve cells were significantly smaller than those from the
TA31
H19high cells. Furthermore, the TA31
H19high -derived tumors
were more vascularized (Fig. 5-bottom). RT-PCR results from the
tumors obtained from TA11
H19-ve showed that H19 RNA was
induced in those tumors as opposed to null expression of H19
RNA in those cells in vitro (data not shown). These results suggest
that H19 RNA enhances tumor growth. To directly assess whether
H19 expression was also essential for the growth of human bladder
carcinoma cells in vivo, we first performed in vitro studies to
determine whether siRNA H19 #1 that targets the H19 message,
knocks-down H19 RNA in the human bladder carcinoma cell line,
UMUC3. As shown, hypoxic conditions increase the H19 RNA
level and the siRNA H19 #1 very significantly knocks it down
(Fig. S5A). The UMUC3 cells were in-vitro transfected with the
siRNA H19 #1 and then implanted in CD-1 mice as was
performed with the Hep3B HCC cells in vivo studies (Fig. 6). The
knocking-down of H19 message again caused a very significant
retardation of tumor growth of the human bladder carcinoma cell
Figure 1. H19 RNA is largely induced in response to hypoxic stress and moderately by hypoxia-mimicking condition triggered by CoCl2 in
Hep3B. Hep3B cells were cultured under normal culture conditions for 24 hours before hypoxic or CoCl2 manipulation. Cells were either placed into
an aneoropack rectangular jar to create a hypoxic condition within an hour, or left under normal culture conditions. Incubation lasted for 24 hours
before RNA extraction. (A) Shown are RT-PCR products of H19 gene (28 PCR cycles) cultured under normal conditions-lane 1, or hypoxic conditions-
lane 2 (lane M indicates the marker, and C is a PCR blank without a target). (B) PCR for Histone H3.3 as a positive control for RT-PCR integrity. Shown
also are RT-PCR products of both the H19 gene (32 PCR cycles) (C), the GAPDH gene (D) for untreated Hep3B (lane1) and for 50, 100, 200, 300 and
400 mM CoCl2 treated cells (lanes 2, 3, 4, 5 and 6, respectively). Incubation with the indicated concentrations of CoCl2 lasted for an additional 22 hours
before RNA extraction. QPCR analysis for H19 RNA levels normalized to b-actin in Hep3B treated CoCl2 is shown in (E) where the numbers above the
bars indicate the concentrations of CoCl2 used.
doi:10.1371/journal.pone.0000845.g001
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transfected with GFP siRNA. The fact that the two different
siRNAs targeting the H19 message had an identical effect implies
that the phenotype we observed is not related to an off-target effect
of the siRNA used.
Knocking down H19 RNA suppresses p57
kip2 and
abolishes its induction in response to hypoxic stress
Regional coordination of gene expression and repression is found
in many imprinted gene clusters in the mammalian genome and is
regulated by imprinting centers or imprinting control regions. A
well characterized cluster is one containing the paternally
expressed IGF2 and maternally expressed H19 in chromosome
11p15.5. In this study, we chose to test the expression of the cell-
cycle inhibitor p57
kip2; it is the only imprinted cyclin-dependent
kinase inhibitor and is located within the same cluster of imprinted
genes where H19 is present [39]. Moreover, recent reports have
shown a decrease in the expression of p57
kip2 in HCC compared
to normal liver cells [40]. To delineate the effect of H19 levels on
p57
kip2 levels, we knocked-down H19 levels with siRNA H19 #3
in the Hep3B cell line, and siRNA H19 #1 in UMUC3 under
both normal and hypoxic conditions. As shown in (Fig. 7B), and
(Fig. S5B), the knocking-down of H19 RNA resulted in nearly
complete attenuation of p57
kip2 induction in response to hypoxic
stress in both cell lines; moreover, using two different siRNAs
targeting H19 strongly indicates the specificity of the results. The
expression of p19
INK4 was not affected as tested in the Hep3B cell
line (Fig. 7C).
H19 knockdown modulates the expression of genes
involved in angiogenesis, survival and
tumorigenesis in hypoxic stress
To further determine the different targets and pathways which are
affected by H19 RNA, we undertook a comprehensive experi-
mental approach by performing a differential gene expression
analysis. The effects of the knocking-down of H19 RNA in Hep3B
cells have been examined on two gene categories: 1. Hypoxia-
responsive genes modulated by H19 RNA knockdown as shown in
Tables 1 and 2; and 2. Genes not responsive to hypoxia that show
modulation of expression by H19 RNA knockdown in hypoxic
stress (same Tables-genes marked with a *). We demonstrate that
H19 RNA regulates the expression of arrays of gene products that
mediate some aspects of the tumorigenic processes that is not only
essential for cell survival and angiogenesis, but also accounts for its
tumorigenic potential under hypoxic conditions by modulating the
mRNA levels of putative oncogenes and tumor suppressor genes.
Knocking down H19 RNA reduced the expression of 60 genes and
upregulated the expression of 27 genes under these categories.
Among genes modulated by H19 knockdown, are those that
modulate angiogenesis and blood vessels development . H19 RNA
knockdown affects the hypoxic responsiveness of the potent
angiogenic factors ANG [41], FGF18 [42], prolylcarboxypeptidase
(PRCP) or angiotensinase c [43], tumor necrosis factor, alpha-
induced protein 1 (endothelial) (TNFAIP1) also known as (B61)
[44] Calponin2 (CNN2) [45] and inhibitor of DNA binding 2 (Id2)
[46], where they show significantly lower expression levels in
response to hypoxia relative to cells possessing H19 RNA.
Furthermore, an upregulation of two putative angiogenic
inhibitors are noted, namely Angiopoietin-like 4 (ANGPTL4),
and Ephrin A1 (EFNA1) [47].
Moreover, the mRNA levels of many genes implicated in
survival/apoptotic decision displayed modulated levels of expres-
sion by H19 knockdown in hypoxic stress. H19 knockdown
downregulates the mRNA levels of microphthalmia-associated
transcription factor (MITF) [48], immediate early response 3
(IER3) [49], protein kinase C, zeta (PRKCZ) [50], B-cell CLL/
lymphoma 3 (BCL3) [51], and (Akt-1) [52], all reported as having
antiapoptotic function, whereas, the DNA-damage-inducible
transcript 3 (DDIT3) also known as (GADD153) is upregulated
[53]. Semiquantitative RT-PCR validated changes in the
expression levels of some of the genes are shown in (Fig. 8). These
included ANG, FGF18 and Akt-1. As shown in (Fig. 8C), knocking
down H19 RNA resulted in severe attenuation of ANG induction
in response to hypoxic stress, and abolished its expression under
normoxic conditions. This also holds true for FGF18 (Fig 8A).
Whereas, Akt-1 is not a hypoxia-responsive gene, a pronounced
reduction in its level was noted by H19 knockdown in hypoxia
(Fig. 8E).
Putative tumor suppressor genes are upregulated by H19
knockdown in hypoxic stress. These include polo-like kinase 2
(PLK2) [54], mitochondrial tumor suppressor 1 (MTUS1) [55],
regulator of G-protein signaling 2 (RGS2) [56], cylindromatosis
(CYLD) [57], tribbles homolog 1 (TRIB1) [58], caveolin-1 (Cav-1)
[59] and BTG family member 3 (BTG3) [60]. On the other hand,
genes that are reported to manifest upregulation in a variety of
tumors in a number of models and having tumor promoting
activities are downregulated. These include the estrogen receptor-
binding fragment-associated antigen 9 (EBAG9) [61], fascin
homolog 1 (FSCN1) [62], alpha-methylacyl-CoA racemase
(AMACR) [63], tumor protein D52 (TPD52) [64], uroplakin 1A
(UPK1A) [65], myeloid differentiation primary response gene (88)
(MYD88) [66], transcription factor 2 (TCF2) [67], Phospholipase
Figure 2. Effect of four different H19 siRNA duplexes on the
expression level of H19 in the Hep3B cell line under normal culture
condition (A) and hypoxia-mimicking CoCl2 treatment (B). Shown is
H19 RNA levels (34 PCR cycles) in (A): Hep3B cells transfected with
unrelated siRNA duplex that targets luciferase gene (lane 1) and with 4
different H19 siRNA1 to H19 siRNA4 duplexes (lanes 2–5) and an
equimolar mixture of the four siRNAs (lane 6); for controls, we
performed transfection also with lipofectamine 2000 without siRNA
(Mock) (lane 7) and C is PCR blank without a target. (B): Hep3B cells
were transfected under normal medium with siRNA duplex that targets
the luciferase gene (lanes 1 and 5) and with 3 different H19 siRNA
duplexes (lanes 2–4). Twenty four hours post transfection, media was
changed, and 100 mM CoCl2 containing media was added except for
lane 5 which continued to grow under normal culture media; the
incubation lasted for an additional 22 hours. (C): Shown are RT-PCR
products of GAPDH gene as a positive control for RT-PCR integrity.
doi:10.1371/journal.pone.0000845.g002
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e845Figure 3. H19 RNA is induced by hypoxic stress in Hep3B cell line and siRNA directed against H19 very efficiently impedes its induction. Hep3B
cells were seeded and transfected either with H19 siRNA or luc siRNA . Twenty four hours post transfection, cells were either placed into an
aneoropack rectangular jar , or left under normal oxygen concentration. Incubation lasted for 24 hours before RNA extraction. Shown are RT-PCR
analyses for H19 RNA (28 PCR cycles). (A): Hep3B transfected with Luc siRNA (lanes 1, 2) and H19 siRNA (lanes 3, 4) both in normal (lanes 1, 3) and
hypoxic (lanes 2, 4) culture conditions, respectively. PCR analysis of a house-keeping gene Histone H3.3 (B), and uPAR (C). In (D) QPCR analysis for H19
RNA levels normalized to b-actin in Hep3B cells is depicted.. A Quantitative SYBR Green RT–PCR was performed on human total RNA for both H19 and
b-actin to estimate H19 RNA copy number under different manipulations and efficiency of knockdown under hypoxic conditions.
doi:10.1371/journal.pone.0000845.g003
Figure 4. Transient H19 RNA knockdown in Hep3B cells inhibited tumorigenicity in vivo. Hep3B cells were transiently transfected with H19 siRNA3
or Luc siRNA. Forty eight hours post transfection, cells were washed twice with PBS, trypsinized and counted. Equal numbers of cells (1.5610
6) were
injected subcutaneously into the dorsal part of CD-1 nude mice (n=7 for both, and 4 for mock transfected). Palpable tumors were observed 15 days
post inoculation in mice inoculated with Hep3B, transiently transfected with Luc siRNA. Tumor volumes were followed up and measured using
a caliper until day 30 post inoculation, after which mice were sacrificed. Significant (p,0.03) reductions of about 82% of both mean tumor weights
(A) (6 standard error) and mean tumor volumes (p,0.03) (B) (6 standard error) were observed. Values represent end-points just before and after
sacrificing animals. Shown are also representative features of tumors in 2 mice of each group (mice 1 and 2 are the H19 siRNA3 treated Hep3B cells,
and mice 3 and 4 are the Luc siRNA ) before tumor surgical exposure (C), and after exposure of their internal tumors (D).
doi:10.1371/journal.pone.0000845.g004
H19 Behaves as an Oncogene
PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e845Figure 5. The effect of over-expression of H19 RNA on the tumorigenic potential of bladder carcinoma cells in vivo. Equal amounts (2610
6)o f
TA31
H19high and TA11
H19-ve cells were implanted subcutaneously to CD-1 mice (n=5, each). Two weeks later, palpable tumors appeared and tumor
volumes were measured for an additional two weeks . Shown are end point measurements of the mean tumor volumes of the two groups (upper left
pannel), their mean tumor volumes kinetics (upper right), and a representative gross morphology of tumors derived from the TA11
H19-ve (lower left)
and TA31
H19high cells(down and right).
doi:10.1371/journal.pone.0000845.g005
Figure 6. The in vivo effect of H19 silencing on the tumorigenic potential of human bladder carcinoma cells-UMUC3. One million UMUC3 cells
were injected subcutaneously to athymic mice (n=3 for GFP siRNA, and 5 for H19 siRNA ), 48 hours after transiently transfected with siRNAs. Palpable
tumors were observed 6 weeks later in 2 out of 3 mice of the GFP siRNA group, while in none of the H19 siRNA group . Mice were sacrificed 8 weeks
after inoculation. Mean tumor volumes (B, P,0.05), and mean tumor weights (A, p,0.06) are depicted. Values represent end-points just before and
after sacrificing animals. Pictures depict the external features of the tumors in mice inoculated with UMUC3 transfected with GFP siRNA (C), and H19
siRNA (D).
doi:10.1371/journal.pone.0000845.g006
H19 Behaves as an Oncogene
PLoS ONE | www.plosone.org 8 September 2007 | Issue 9 | e845A2, group IV (cytosolic, calcium-dependent) ( PLA2G4A) [68] and
those involved in DNA replication and cell cycle progression,
thymidylate synthetase (TYMS) and cyclin E2 (CCNE2) [69].
H19 siRNA very significantly reduced anchorage-
independent growth after hypoxia recovery
To test for the functional consequences of the microarray data
described above, we then evaluated the effect of H19 suppression
on anchorage-independent colony formation in soft agar after
hypoxia recovery as an additional assessment of tumorigenicity in
vitro. Hep3B cells were exposed to hypoxic stress 4 hours post
transfection as indicated in Materials and Methods. Twenty four
hours post hypoxic conditions, cells were seeded on soft agar. H19
knocking- down very significantly abrogated anchorage indepen-
dent growth after hypoxia recovery as both colony number and
size were reduced (Fig. S6).
DISCUSSION
In this study, we used a powerful gene-silencing strategy (RNAi) to
knock down the H19 RNA in cellular and animal tumor models.
Our results highlight a critical role of H19 RNA in tumor
development, and in particular in the growth of HCC. Our results
indicate a direct effect of H19 RNA on tumor growth, and a strong
association between hypoxia and H19 levels. Altogether, these
data coupled with a wealth of information in the literature on the
high expression level of the H19 gene in tumor tissue, identify H19
as having a pivotal role in tumor development.
Clonal evolution of tumor cells in the hypoxic microenviron-
ment results from selection of subpopulations that not only resist
apoptosis, but also promote the formation of blood vessels. The
role of hypoxia in tumorigenesis can be mediated through its
effects on oncogene/tumor suppressor genes expression. In this
study, we investigate the transcriptional profiles of two populations
of Hep3B cells that differ in the RNA level of the hypoxia
responsive gene H19, under hypoxic conditions. The effects of loss
of H19 gene expression in Hep3B cells have been examined in two
gene categories: 1. Hypoxia responsive genes modulated by H19
knockdown (Tables 1 and 2); and 2. Genes not responsive to
hypoxia, showing modulation of expression by H19 knockdown
under hypoxic stress (same Tables-genes marked with an *).
Little is known today about the function of H19 RNA; however,
several lines of evidence supporting the involvement of H19 RNA
in hypoxic stress response have accumulated during the past few
years. We previously identified downstream targets modulated by
H19 over-expression in the T24P bladder carcinoma cell line.
Functional grouping of genes whose expression were modulated by
H19 RNA showed trends towards genes promoting cellular
migration, angiogenesis and metastasis. Notably, several of those
genes upregulated by the presence of H19 RNA were also known
to be induced by hypoxia [33]. Moreover, a proteomic approach
has revealed that H19 overexpression in human cancerous
mammary epithelial cells positively regulated the thioredoxin gene
at the post-transcriptional level, thioredoxin being a key protein of
the oxidative stress response and in the reduction of ribonucleo-
tides to deoxyribonucleotides enabling DNA synthesis and the
passing of the cells through the S-phase. [70]. Numerous
physiological processes involving cellular invasion, blastocyst
implantation, and placental development occur under reduced
oxygen environments [71]. We have shown that these physiolog-
ical processes manifested high levels of H19 RNA [23]. Thus, it
seemed logical to test whether H19 RNA levels are modulated
under hypoxic stress. In one specific tumor such as human
hepatocellular carcinoma (HCC), H19 RNA levels are much
higher in both the primary and the metastatic tumor than in
normal liver (Fig. S1). Our observation that H19 increases under
hypoxic stress conditions could imply the relevance of the targets
which are those associated with stress activations.
There are several controversial reports in the literature
discussing H19 gene function. A tumor suppressor activity was
postulated showing that H19 overexpression lowered the tumor-
igenic properties of cells derived from kidney tumor [72].
Moreover, the H19 gene is frequently inactivated in Wilms tumor
[73]. However, H19 is either highly expressed and/or manifest an
Figure 7. H19 RNA knockdown impedes p57Kip2 mRNA induction in response to hypoxic stress, in Hep3B cell line. Hep3B cells were seeded and
transfected either with H19 siRNA or Luc siRNA as described . Shown are RT-PCR analyses for H19 RNA (28 PCR cycles). (A): Hep3B transfected with luc
siRNA (lanes 1, 2) and H19 siRNA (lanes 3, 4) both in normal (lanes 1, 3) and hypoxic (lanes 2, 4) culture conditions, respectively. And similar treatments
are assessing the mRNA levels of: (B). p19
INK4 (C). p57
Kip2 (D). Histone.
doi:10.1371/journal.pone.0000845.g007
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PLoS ONE | www.plosone.org 9 September 2007 | Issue 9 | e845Table 1. Genes reduced by at least two-folds by H19 knockdown in hypoxic stress.
..................................................................................................................................................
Gene Symbol Gene name Folds Change Functional Category
Angiogenesis
TNFAIP1 Tumor necrosis factor, alpha-induced protein 1 (endothelial) 2.0 Immune response/angiogenesis
CNN2* calponin 2 2.1 Cytoskeleton
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 2.7 Development
PRCP prolylcarboxypeptidase (angiotensinase C) (not hypoxia) 2.0 Proteolysis
ANG angiogenin 2.5 Angiogenesis
RNASE4 ribonuclease, RNase A family, 4 3.0 mRNA cleavage/Angiogenesis
FGF18 fibroblast growth factor 18 Growth factor activity
Anti-apoptotic/Survival
IER3 immediate early response 3 2.5 Anti-apoptosis
PRKCZ protein kinase C, zeta 2.2 Anti-apoptotic
AKT1* v-akt murine thymoma viral oncogene homolog 1 3.2 Anti-apoptotic
MITF* microphthalmia-associated transcription factor 2.1 Regulation transcription/differentiation
Cytoskeleton
TUBB2A* tubulin, beta 2 2.4 Cytoskeleton
DBN1* drebrin 1 3.4 Actin filament organization
FHOD3* formin homology 2 domain containing 3 2.4 Actin cytoskeleton
FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) 9.0 Actin cytoskeleton/proliferation
SNTA1 syntrophin, alpha 1 (dystrophin-associated protein A1, 59kDa, acidic
component)
3.3 Actin cytoskeleton
MARK4 MAP/microtubule affinity-regulating kinase 4 3.4 Microtuble bundle formation
KIF3C* kinesin family member 3C 3.0 Microtubule based movement
Metabolism
ALDH1A3* aldehyde dehydrogenase 1 family, member A3 2.8 Metabolism
PLA2G4A Phospholipase A2, group IV (cytosolic, calcium-dependent) 3.2 Lipid catabolism
CORO2A coronin, actin binding protein, 2A 2.2 Nitrogen compounds metabolism
PLSCR4* phospholipid scramblase 4 2.0 Phospholipids scrambling
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha 3.8 Metabolism
MPI mannose phosphate isomerase 4.4 Carbohydrate metabolism
AMACR* alpha-methylacyl-CoA racemase 2.7 Metabolism
Cell cycle/Growth
EBAG9 Estrogen receptor binding site associated, antigen, 9 5.0 Regulation of cell growth.
RASSF2 Ras association (RalGDS/AF-6) domain family 2 2.0 Cell cycle-signal transduction.
BCL3 B-cell CLL/lymphoma 3 2.0 Proto-oncogene
TYMS* thymidylate synthetase 2.4 DNA replication
CCNE2 cyclin E2 2.3 Cell cycle
Signal transduction/transcription
TRAF3IP2 TRAF3 interacting protein 2 2.6 Signal transducer activity.
RXRA retinoid X receptor, alpha 3.1 Nuclear receptor, transcription activator
TCF2* transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor 3.3 Transcription factor
JARID2 Jumonji, AT rich interactive domain 2 3.8 Transcription/development
IL1RAP Interleukin 1 receptor accessory protein 2.1 Inflamatory response
UPK1A uroplakin 1A 2.1 Signal transduction/deffirentiation
MYD88* Myeloid differentiation primary response gene (88) 2.2 NF-KappaB cascade
PIP5K2B Phosphatidylinositol-4-phosphate 5-kinase, type II, beta 2.0 Signal transduction
CTNNBIP1 catenin, beta interacting protein 1 2.3 Wnt receptor signaling pathway
PEX11A* Peroxisomal biogenesis factor 11A 2.3 Signal transduction
KIAA1196* KIAA1196 2.4 Regulation transcription
ZNF189* zinc finger protein 189 2.2 Metal ion binding/ Transcription
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PLoS ONE | www.plosone.org 10 September 2007 | Issue 9 | e845aberrant allelic pattern of expression in over 30 types of cancer
[74], suggesting that H19 may play a role in tumorigenesis.
p57
kip2 plays a role in many biological events including
differentiation, apoptosis, cell-proliferation and tumorigenesis.
Knocking-down H19 RNA resulted in nearly complete attenu-
ation of p57
kip2 induction in response to hypoxic stress in both
Hep3B and UMUC3 cell lines. Although it is not surprising that
there may be reciprocity or dependency of expression between
imprinting intra-cluster gene expression, the significance of this
finding in hepatocarcinogenesis needs further investigation.
p57
kip2, a KIP family cyclin-dependent kinase (Cdk) inhibitor,
blocks the cell cycle by acting on multiple cyclin-Cdk complexes.
Overall, recent reports on the function of p57
kip2 point to its role
in cell cycle exit rather than a supporter of cellular proliferation.
Further investigation is needed to unfold its role in the
development of HCC. Furthermore, we also show by RT-PCR
analysis that IGFBP4 is upregulated by H19 knockdown
irrespective of a hypoxic state (Fig. 8B). IGFBP4 is an inhibitor
of the IGF system including IGF2, which reside in close
proximity to the H19 gene, and reciprocally imprinted. Although
a wealth of information exists on the regulation of those
imprinted genes in cis, little is known about trans-regulation.
Our observation that knocking down H19 upregulates IGFBP4,
which counteracts the tumor promoting activity of IGF2, could
provide a link in trans between H19 and IGF2. Moreover,
IGFBP4 is shown to have anti-angiogenic and anti-tumorigenic
properties [75].
Currently, H19 RNA does not stand alone as an RNA molecule
with a direct effect on tumorigenesis. There is evidence that
microRNAs can act as oncogenes or tumor suppressors. The miR-
17-92 cluster of microRNAs augments the oncogenic effect of the
c-Myc in mice [76]. Furthermore, it was found that this cluster,
when up-regulated by the expression of c-Myc, down-regulates the
expression of the E2F1 protein — one of the transcriptional targets
of c-Myc—at the translational level. These findings suggest that
the miR-17-92 cluster can act as an oncogene or as a tumor
suppressor [76,77]. Interestingly, the RAS oncogene is regulated
by the let-7 microRNA; decreased expression of let-7 microRNA
in some human lung tumors causes increased expression of the
RAS oncogene and thereby may contribute to tumorigenesis.
Altogether, there is a growing amount of evidence supporting the
role of RNA molecules as controllers of tumor development. H19
is predicted to have a complex secondary structure which could
serve as a substrate for Drosha. A recent report suggested that H19
is a precursor for microRNA 675 [78].
Further studies are necessary to unfold the molecular mech-
anism(s) controlling the expression of the imprinted gene H19 and
its role in tumor development. In this study, we have shown that
H19 acts like an oncogene, and we identified some of its
downstream targets. Our results, together with recent reports
[16,17] suggest that H19 RNA harbors oncogenic properties,
promoting tumorigenesis. Recently, Barsyte-Lovejoy D et al.,
concluded that the c-Myc oncogene directly induces the H19
RNA and therefore potentiates tumorigenesis. Downregulation of
H19 RNA significantly decreased breast and lung cancer cell
clonogenicity and anchorage-independent growth [27]. These
results together with ours suggest that H19 acts as an oncogene,
and we propose that this effect could be triggered by hypoxic stress
[79]. Although the oncogenic mechanism(s) of H19 needs further
investigation, the fact that H19 is highly expressed in many types
of tumors in a relatively high percentage of cases points to H19 as
a target for cancer gene therapy.
Gene Symbol Gene name Folds Change Functional Category
Miscellaneous
ZNF185 Zinc fingure protein 185 (LIM domain) 2,3 Metal ion binding
USP3 ubiquitin specific peptidase 3 3.4 Ubiquitin dependent protein
catabolism
RAB4A RAB4A, member Ras oncogene family 2.2 Protein transport
ATP13A2 ATPase type 13A2 2.2 Cation transport/metabolism
SYNGR3 synaptogyrin 3 2.6 Membrane protein
MTMR4 myotubularin related protein 4 2.2 Phospholipids dephosphorylation
DAG1* dystroglycan 1 (dystrophin-associated glycoprotein 1) 2.1 Laminin receptor activity
GLTP glycolipid transfer protein 2.1 Glycolipid transport
RAD23B* RAD23 homolog B (S. cerevisiae) 2.1 Nucleotide-exision repair
INPP5A* inositol polyphosphate-5-phosphatase, 40kDa 2.4 Hydrolase activity/ Cell comunication
SNPH* syntaphilin 2.5 Synaptic vesicle docking
FKBP9 FK506 binding protein 9, 63 kDa 2.8 Protein folding
TPD52 ’tumor protein D52 3.0 Secretion/deffirentiation
Unknown
KIAA0802 KIAA0802 2.0
DENND3 DENN/MADD domain containing 3 2.4 Unknown
ZNF668* zinc finger protein 668 2.0 Unknown
KIAA0802 KIAA0802 3.8 Unknown
KIAA1598* KIAA1598 2.8 Unknown
Hypothetical protein LOC221362* 2.9 Unknown
*=Hypoxia non-responsive, but shows decreased expression by H19 knockdown under hypoxic conditions
doi:10.1371/journal.pone.0000845.t001
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Figure S1 H19 is highly expressed in human HCC. A biopsy
from a patient with HCC depicting his primary (A and B) and
intra-vascular metastasis (C and D), stained for a-fetoprotein by
immunohistochemistry (A and C) or by in-situ hybridization for
H19 message (B and D).
Found at: doi:10.1371/journal.pone.0000845.s001 (8.70 MB TIF)
Figure S2 RT-PCR analysis for the expression level of H19 in
different HCC cell lines: (A) RT-PCR analysis for H19 mRNA
was performed on cDNA of the cell lines: Lane 1-SNU 398; Lane-
2 SNU 475; Lane-3 Hep3B; Lane -4 HepG2215 (HBV producing
cell line); Lane -5 HepG2 (parental to HepG2215) ; Lane -6
FLC4A10 (HBV producing cell line; Lane -7 FLC4 (parental to
FLC4A10) ; Lane-8 Huh7; and Lane -9 the bladder carcinoma cell
line T24P. C- is the blank. The RT-PCR was carried as described
in Materials and Methods. (B) The efficiency of the RT-PCR
analysis was tested using GAPDH-specific primers. (C) QPCR
analysis of some of the samples mentioned above.
Found at: doi:10.1371/journal.pone.0000845.s002 (0.23 MB TIF)
Figure S3 Knocking down kinetics of the H19 gene in Hep3B
cell line: H19 and luciferase specific siRNAs were transfected into
Hep3B cell line as indicated using the most potent siRNA
identified for the H19 gene. At the indicated time points, RNA was
extracted and subjected to RT-PCR analysis. Shown are RT-PCR
products of H19 (34 PCR cycles) (A), and b-actin (B). Single
numbers are RT-PCR products for Hep3B cells transfected with
Luc siRNA and odds are for H19 siRNA. C=PCR blank. RNA
was extracted at 1, 6, 9 and 12 day’s intervals, respectively from
transfection.
Found at: doi:10.1371/journal.pone.0000845.s003 (1.47 MB TIF)
Figure S4 The effect of knocking-down H19 RNA on the
growth of Hep3B cells in vitro: Hep3B cells were seeded and
transfected with GFP siRNA or H19 siRNA. Twenty four hours
Table 2. Genes induced by at least two-folds by H19 knockdown under hypoxic stress.
..................................................................................................................................................
Gene Symbol Gene name Folds Change Functional Category
Putative tumor suppressor activity/ Antiproliferative
CYLD* cylindromatosis (turban tumor syndrome) 3.1 Cell cycle
MTUS1* mitochondrial tumor suppressor 1 3.2 Receptor activity
PLK2* polo-like kinase 2 (Drosophila) 2.0 Signal transducer
RGS2 regulator of G-protein signalling 2, 24kDa 2.8 Signal transduction
CAV1* caveolin 1, caveolae protein, 22kDa 2.4 Cholestrol hemeostasis
BTG3 BTG family member 3 3.6 Antiproliferative
TRIB1 tribbles homolog 1 (Drosophila) 6.9 Regulation MAPK activity
Putative Anti-Angiogenesis activity
EFNA1 ephrin-A1 3.9 Ephrin receptor binding
ANGPTL4 Angiopoietin-like 4 2.4 Angiogenesis/metabolism
Pro-apoptotic factors
DDIT3 DNA-damage-inducible transcript 3 4.0 Growth arrest/apoptosis
CASP3 Caspase 3 2.7 Apoptosis
Metabolism
PYGB* Phosphorylase, glycogen; brain 2.6 Carbohydrate metabolism
SREBF1 sterol regulatory element binding transcription factor 1 2.6 Metabolism
GPD1L glycerol-3-phosphate dehydrogenase 1-like 2.0 Metabolism
SMS* Spermine synthase 2.1 Polyamine metabolism
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 4.6 Metabolism
Miscellaneous
SNAPC1 small nuclear RNA activating complex, polypeptide 1, 43kDa 2.2 Transcription
TSN Translin 2.0 DNA recombination
RNMT RNA (guanine-7-) methyltransferase 4.4 mRNA capping
C10orf10 C10orf10 2.5 Fasting induced
MAPK6 mitogen-activated protein kinase 6 3.4 Signal transduction
C1orf9 C1orf9 2.1 Transmembrane protein
NUPL1 Nucleoporin like 1 3.7 Transport
TMEM2 Transmembrane protein 2 4.6 Transmembrane protein
Uncharacterized
hypothetical protein DKFZp762E1312* 2.4 Unknown
hypothetical protein FLJ13611 2.3 Unknown
COL13A1 collagen, type XIII, alpha 1 2.6 Unknown
*=Hypoxia non-responsive, but shows decreased expression by H19 knockdown under hypoxic conditions
doi:10.1371/journal.pone.0000845.t002
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56103 cells were seeded in quadruples for each group, incubated
for 24 hours before MTS assay was performed and measured with
an ELISA plate reader. Each bar represents the mean6standard
error of 4 replicates.
Found at: doi:10.1371/journal.pone.0000845.s004 (0.99 MB TIF)
Figure S5 Knockdown of H19 RNA impedes p57Kip2 in-
duction in response to hypoxic stress in UMUC3 cell line:
UMUC3 cells are manipulated as indicated in the legend of Fig1c,
with the exception that GFP siRNA is used as a negative control of
transfection, and H19 siRNA #1 was used. (A): UMUC3
transfected with GFP siRNA (lanes 1,3) and H19 siRNA (lanes
2,4) both in normal (lanes 1,2) and hypoxic (lanes 3,4) culture
conditions respectively, shows again an upregulation of H19 RNA
(28 PCR cycles) in response to hypoxic stress (lanes 1,3) and a very
efficient knockdown ability (lanes 2,4). (B): RT-PCR analysis of
p57Kip2 shows that it is only induced in GFP siRNA negative
control treated cells lanes (1, 3), but not in H19 siRNA treated cells
(lanes 2, 4). (C): RT-PCR analysis of b-actin.
Found at: doi:10.1371/journal.pone.0000845.s005 (1.41 MB TIF)
Figure S6 H19 depletion suppresses anchorage independent
colony formation after hypoxia recovery. Equal numbers of
Hep3B cells (2.5*103), which were previously transfected with
GFP siRNA and H19 siRNA and exposed to hypoxic stress for
24 hours, were seeded into 6-wells plates containing 0.3% top low-
melt agarose-0.8% bottom low-melt agarose, 6-wells per each
manipulation. After 4 weeks, colony formation was scored
microscopically. Each bar represents the mean6standard error
of 6 replicates. Significant (p=0.001) reduction of about 68% of
colony forming ability was observed on those transfected with H19
siRNA.
Found at: doi:10.1371/journal.pone.0000845.s006 (0.62 MB TIF)
Table S1 siRNA duplexes targeting the human H19 RNA
Found at: doi:10.1371/journal.pone.0000845.s007 (0.03 MB
DOC)
Table S2 Percent expression of H19 in human tumors
Found at: doi:10.1371/journal.pone.0000845.s008 (0.05 MB
DOC)
Table S3 Loss of imprinting of the H19 gene in human cancer
Found at: doi:10.1371/journal.pone.0000845.s009 (0.05 MB
DOC)
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